Tesaro - Company Information
GlaxoSmithKline is a global healthcare company that focuses on pharmaceuticals, vaccines, and consumer healthcare products, with a wide range of offer...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolGSK
Websitegsk.com
TypePublic
Tesaro Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Tesaro
Twitter is a microblogging and social networking service on which users post and interact ...
SEMrush
SEMrush is a marketing toolkit designed for digital marketing professionals, with tools fo...
Tesaro Employee Profiles
Are you looking for the decision-makers at Tesaro? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Tesaro’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of Tesaro employees
Install Now
Tesaro News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Tesaro latest news, alerts and updates.
GSK concludes acquisition of BELLUS Health
Upon completion of the Arrangement, GSK acquired all outstanding common shares of BELLUS for US$14.75 per common share in cash, representing a total equity value of US$2.0 billion.
29 Jun 2023
GSK completes acquisition of chronic cough-focused Bellus Health
GSK PLC on Wednesday said it completed its acquisition of Quebec-based late-stage biopharmaceutical firm Bellus Health Inc for a total equity value of USD2.0 billion. GSK, the Brentford, London-based pharmaceutical company,
28 Jun 2023
GSK Reaches Agreement To Acquire Late-Stage Biopharmaceutical Company BELLUS Health
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and po
19 Apr 2023
GSK to acquire Canadas Bellus Health for $14.75 per share
GSK said the deal will provide access to camlipixant, a treatment for refractory chronic cough currently in phase III development.
18 Apr 2023
FAQs for Tesaro
Explore frequently asked questions about Tesaro’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
Get instant access to B2B contact data across the web
Sign Up Today
